Phase 1 BALLI-01 data showed UCART22 induced remissions with limited severe CRS/ICANS in relapsed/refractory B-cell ALL, supporting phase 2.
Nitin Jain, MD
Advertisement
Nitin Jain, MD, is a professor of medicine in the department of leukemia at the University of Texas MD Anderson Cancer Center.
Articles by Nitin Jain, MD
EHA 2026 highlights include advances in immunotherapy across blood cancers.
Phase 1 BALLI-01 trial results showed promising UCART22 activity in R/R B-cell ALL, with higher remission rates after a manufacturing change.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Atacicept for IgA Nephropathy
2
340B Drug Payment Cuts Headline CMS Proposal to Lower Medicare Costs
3
Ebola Cases Top 1700 as Unpaid Health Workers Strike
4
IL-6, Not hsCRP, Modified Lp(a)-Associated CAD Risk
5